AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28660719
Drug: Participants not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants not using insulin in the control group
Trial: 20186397
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered oxytocin
Trial: 15126990
Drug: Laronidase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laronidase (100 U/kg, 0.58 mg/kg) administered intravenously weekly for 26 weeks
Trial: 15126990
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously weekly for 26 weeks
Trial: 9143566
Drug: Intravenous gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gentamicin and chloramphenicol
Trial: 3240302
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk supplemented with 1 mmol NaH2PO4 per 100 ml
Trial: 28389125
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antiplatelet, statin and blood pressure lowering drugs
Trial: 28389125
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of BP-lowering drugs and statins at discharge
Trial: 18667842
Drug: Topical methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methimazole 5%
Trial: 18667842
Drug: Oral methimazole
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methimazole 5 mg tablet
Trial: 19363280
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg daily for 20 days
Trial: 14766711
Drug: Urapidil 10-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 10-15 mg h(-1) continuous i.v. infusion for 3 days before surgery and until adrenal gland removal
Trial: 26142266
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy optimization
Trial: 20214337
Drug: CPSG 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPSG 5 g per day for 2 weeks
Trial: 15105217
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg and Placebo
Trial: 11298484
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (Aldara)
Trial: 23963030
Drug: Intra-arterial octreotide
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial octreotide (5 mL 500µg)
Trial: 23963030
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 mL 0.9% saline solution)
Trial: 3816920
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (500 mg)
Trial: 3816920
Drug: Captopril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (40 +/- 13 mg)
Trial: 30329160
Drug: 3-dimensional conformal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dimensional conformal radiation therapy (3DCRT)
Trial: 18800957
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg PO BID
Trial: 15785917
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance with mandible advance (12 patients)
Trial: 15785917
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance without mandible advance (12 patients)
Trial: 12719065
Drug: Self-administered health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered health status questionnaire
Trial: 10875161
Drug: Rufloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rufloxacin (200 mg single oral dose three hours before surgery)
Trial: 25727335
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (NaCl 0.9%)
Trial: 12534583
Drug: Aspirin 500
RxNorm normalized name: aspirin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 500 mg
Trial: 1391958
Drug: OKY-046 400
RxNorm normalized name: OKI-179
DrugBank: OKI-179 (DB17583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY-046 400 mg
Trial: 30921401
Drug: Antibiotic impregnated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic impregnated CVCs
Trial: 30921401
Drug: Heparin bonded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bonded CVCs
Trial: 22026446
Drug: Warfarin re-administration
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin re-administration 3 days after burr hole drainage to reach target INR range of 1.7-2.5
Trial: 22026446
Drug: Warfarin re-administration
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin re-administration 3 days after burr hole drainage
Trial: 16160759
Drug: Project ALERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project ALERT drug prevention program
Trial: 11711839
Drug: Latanoprost ophthalmic
RxNorm normalized name: latanoprost ophthalmic
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost ophthalmic solution
Trial: 7900456
Drug: combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined chemotherapy with tranquilizers, antidepressants, neuroleptics
Trial: 2452920
Drug: Indoramin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (50 mg daily for 8 days)
Trial: 2452920
Drug: Indoramin (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (chronic administration)
Trial: 20811347
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEIs)
Trial: 2441167
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 mg terazosin
Trial: 2441167
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 mg prazosin
Trial: 18204417
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) co-administered with other bipolar medications
Trial: 8976948
Drug: iodixanol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol (320 mg I/ml)
Trial: 8976948
Drug: iodixanol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol (300 mg I/ml)
Trial: 31185379
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rheumatoid factor, matrix metalloproteinase‐9 and total homocysteine
Trial: 26621634
Drug: 20-µg vitamin
RxNorm normalized name: vitamin E 20 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-µg vitamin D3 daily for 12 weeks
Trial: 23768267
Drug: HPV 16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV 16/18 vaccine
Trial: 22492244
Drug: HAV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAV vaccine
Trial: 11035136
Drug: 4162W94 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4162W94 300 mg i.v. for 5 consecutive days
Trial: 8622092
Drug: Sustained-release hydromorphone
RxNorm normalized name: hydromorphone Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release hydromorphone (SRH)
Trial: 8622092
Drug: Immediate-release hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release hydromorphone (IRH)
Trial: 31600343
Drug: ART at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART at any CD4 cell count with enhanced support for ART and substance use treatment
Trial: 27484880
Drug: Tamoxifen (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (both doses)
Trial: 21750485
Drug: rFVIIa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa (100 mcg/Kg b.w.)
Trial: 10456450
Drug: Dermatan sulphate
RxNorm normalized name: Dermatan sulphate
DrugBank: Dermatan sulfate (DB15880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatan sulphate (600 mg intramuscularly on the second day before surgery, then 300 mg once daily)
Trial: 6284564
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g die i.v. for 7 days
Trial: 6284564
Drug: Gentamicin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 240 mg die i.m. for 7 days
Trial: 31663156
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication review with patient involvement (questionnaire and telephone call with pharmacist)
Trial: 27453302
Drug: Systemic targeted-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic targeted- and immunotherapy (e.g., ipilimumab, pembrolizumab, nivolumab, vemurafenib, dabrafenib plus trametinib)
Trial: 19897678
Drug: T(4) therapy
RxNorm normalized name: 4-T-BUTYLCYCLOHEXANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T(4) therapy
Trial: 10403324
Drug: Six-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-dose regimen of artemether-lumefantrine (480 mg artemether and 2880 mg lumefantrine)
Trial: 10403324
Drug: Four-dose regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-dose regimen of artemether-lumefantrine (320 mg artemether and 1920 mg lumefantrine)
Trial: 21107435
Drug: OM/HCTZ 40/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM/HCTZ 40/12.5 mg
Trial: 21107435
Drug: OM/HCTZ 20/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM/HCTZ 20/12.5 mg
Trial: 21107435
Drug: OM 40
RxNorm normalized name: Aptiom 400mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM 40 mg
Trial: 9542676
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate emollient 0.05% twice daily (n = 41)
Trial: 9542676
Drug: Emollient vehicle
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emollient vehicle twice daily (n = 40)
Trial: 8001065
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (1% applied 4 times a year, 0.7 ml applied interdentally)
Trial: 8001065
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (applied 4 times a year, 0.7 ml applied interdentally)
Trial: 2086824
Drug: CEMT-PI-L (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMT-PI-L (250 mg, 2 times a day)
Trial: 2086824
Drug: CCL (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCL (500 mg, 3 times a day)
Trial: 2086824
Drug: CEMT-PI-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMT-PI-L
Trial: 25468954
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg daily after about 5 months, discontinued after 5 months (Group 1)
Trial: 25468954
Drug: Methimazole (MMI)
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (MMI) treatment with titration regimen, reduced to 2.5 mg every other day after 5 months, discontinued after a further 5 months (Group 2)
Trial: 25468954
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with antithyroid drugs (ATD)
Trial: 23671210
Drug: Artiste Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artiste Assisted Injection System
Trial: 7843592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of l-moprolol and dipivefrin
Trial: 3049116
Drug: Transfer factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer factor (TF) administered to 22 patients with Hodgkin's disease.
Trial: 3049116
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to 25 patients with Hodgkin's disease (control group).
Trial: 31370791
Drug: New treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatment
Trial: 23595003
Drug: 1250 μg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 μg/week (50 000 IU/week, analysed dose 1544 μg/week) followed by 1250 μg/month
Trial: 21636116
Drug: omalizumab (75-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omalizumab (75-375 mg, subcutaneously once every 2 or 4 weeks for 24 weeks)
Trial: 31682972
Drug: LPS administration
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS administration
Trial: 11268375
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with antidepressants (imipramine or fluoxetine)
Trial: 2478336
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen
Trial: 3512149
Drug: 650 mg
RxNorm normalized name: bran 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg acetaminophen
Trial: 10561210
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate 200 mg/d
Trial: 8739857
Drug: multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple injections of insulin alone
Trial: 1928949
Drug: Albuterol followed
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol followed by saline
Trial: 25086831
Drug: Ocular Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ocular Response Analyzer (ORA) with Nelfilcon A (Daily AquaComfort Plus)
Trial: 17196453
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with LDL <100 mg/dl
Trial: 9822313
Drug: 0.5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microg/kg subcutaneous octreotide
Trial: 24859203
Drug: Vedolizumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (300 mg)
Trial: 20439065
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D supplement
Trial: 20439065
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplement only
Trial: 20439065
Drug: Antiosteoporosis medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiosteoporosis medications
Trial: 12954916
Drug: Cholesterol-reducing drugs
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol-reducing drugs
Trial: 1407926
Drug: Subcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous and oral terbutaline
Trial: 28816242
Drug: Basimglurant 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basimglurant 1.5 mg
Trial: 27604770
Drug: DHA (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (400 mg/day)
Trial: 7748048
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and Naproxen
Trial: 24250318
Drug: Bupivacaine wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine wound infiltration (40 ml, 0.25%)
Trial: 24250318
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (40 ml, 0.9%)
Trial: 21336630
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) plus methylphenidate (20-30 mg/day depending on weight)
Trial: 1425865
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg
Trial: 10485504
Drug: lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 15 mg
Trial: 8792693
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg vs lansoprazole 15 mg
Trial: 8792693
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg vs lansoprazole 15 mg
Trial: 6735042
Drug: 40 749
RxNorm normalized name: petrolatum 0.749 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 749 RP 4 mg/kg
Trial: 30198967
Drug: 0.5mg ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg ranibizumab monthly for 12 months
Trial: 15818420
Drug: Scheme I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme I: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 3 days
Trial: 15818420
Drug: Scheme II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheme II: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 4 days
Trial: 15818420
Drug: Treatment (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (both schemes)
Trial: 2035858
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline added to local anesthetic solution (20 mL of 1% plain lignocaine, 20 mL of 0.5% plain bupivacaine) with intramuscular placebo injection of 1.0 mL of 0.9% saline
Trial: 2035858
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL of 0.9% saline added to local anesthetic solution with intramuscular injection of 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline
Trial: 31646981
Drug: nal-IRI (mg/m2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nal-IRI (mg/m2, 46h infusion)/5-FU (2400 mg/m2, 46h infusion)/leucovorin (400 mg/m2, 0.5h infusion) d1 on 14 day-cycles
Trial: 30261853
Drug: 12-week multimodal
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week multimodal intervention including supervised exercise training, home-based walking, supportive nurse-led counseling, and protein supplement after training.
Trial: 30415608
Drug: Standard oncological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oncological treatment
Trial: 8750372
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg alone
Trial: 1665181
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of lisinopril and hydrochlorothiazide
Trial: 26377913
Drug: Opioid combination
RxNorm normalized name: Opioids in combination with antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid combination
Trial: 19476015
Drug: Desloratadine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desloratadine 5.0 mg qd
Trial: 19476015
Drug: Pseudoephedrine 120
RxNorm normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 120 mg bid
Trial: 17179911
Drug: No test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No test solution (Control group)
Trial: 7723267
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (emergency operation in peritonitis or nonoperative management with cleansing enema, purgatives, and infusion-transfusion therapy)
Trial: 7723267
Drug: Emergency colonoscopy
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency colonoscopy and ultrasonic diagnosis with fractional oral treatment using 30% solution of polyethylene oxide-400 and 1% chloramphenicol
Trial: 2521934
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg x2/day for 2 weeks, then 10 mg x2/day)
Trial: 31660826
Drug: Pharmacokinetic AUC‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic AUC‐based chemotherapy
Trial: 31660826
Drug: BSA guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSA guided chemotherapy
Trial: 23873171
Drug: HPV16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16/18 vaccine
Trial: 19326811
Drug: Piper longum
RxNorm normalized name: piper longum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piper longum (15 mg)